DNA polymerase/reverse transcriptase · SINGLE PROTEIN · Hepatitis B virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13DNA polymerase/reverse transcriptase shows approved-linked disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9IF40. Start with chronic hepatitis B virus infection, then reuse UniProt Q9IF40 as the stable protein anchor across project notes and exports.
Start with chronic hepatitis B virus infection, then reuse UniProt Q9IF40 as the stable protein anchor across project notes and exports.
DNA polymerase/reverse transcriptase shows approved-linked disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.
Start review with chronic hepatitis B virus infection because it currently carries approved-linked support. Linked drugs include ADEFOVIR, ADEFOVIR DIPIVOXIL, ELVUCITABINE, ENTECAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProtein P
Review this target as DNA polymerase/reverse transcriptase, mapped to UniProt Q9IF40. ChEMBL maps the protein component as Protein P. Sequence length is 832 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats DNA polymerase/reverse transcriptase as ChEMBL target CHEMBL2362994, mapped to UniProt Q9IF40. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether DNA polymerase/reverse transcriptase is the right protein anchor across sources, using UniProt Q9IF40 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic hepatitis B virus infection is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | DNA polymerase/reverse transcriptase |
| Target Type | SINGLE PROTEIN |
| Organism | Hepatitis B virus |
| UniProt | Q9IF40 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Protein P |
| UniProt Accession | Q9IF40 |
| Component Type | Protein |
| Sequence Length | 832 aa |
Protein P
Review this target as DNA polymerase/reverse transcriptase, mapped to UniProt Q9IF40. ChEMBL maps the protein component as Protein P. Sequence length is 832 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
DNA polymerase/reverse transcriptase shows approved-linked disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block.
Start review with chronic hepatitis B virus infection because it currently carries approved-linked support. Linked drugs include ADEFOVIR, ADEFOVIR DIPIVOXIL, ELVUCITABINE, ENTECAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.